Tag: Patent expiration

As of September 2025, there is no FDA-approved generic version of Zepbound (tirzepatide) available in the United States [1.2.1]. This is due to extensive patent protections held by its manufacturer, Eli Lilly, which delay the entry of lower-cost generic competitors into the market.

Despite the massive demand for semaglutide, the active ingredient in popular drugs like Ozempic and Wegovy, there is currently no FDA-approved generic form available in the United States. This absence is due to robust patent protection and a complex regulatory landscape that affects both cost and access.

In 2023, nearly 80,000 overdose deaths in the U.S. involved opioids [1.8.5]. For those seeking treatment for opioid use disorder (OUD), a key question is: **is there a generic form of Sublocade?** Currently, the answer is no [1.2.1].

As of late 2025, there is no generic for Fasenra injection, because it is a biologic medication, not a traditional chemical drug. Instead of generics, complex biologics like Fasenra (benralizumab) may one day have "biosimilars," but these are not yet approved.

As of late 2025, there is no generic form of Nextstellis available for prescription in the United States, as the brand-name medication remains under patent protection. Developed by Mithra and marketed by Mayne Pharma, this specific oral contraceptive is a brand-exclusive product.

As of 2025, there is no generic for Eysuvis (loteprednol etabonate ophthalmic suspension) on the market due to active patents protecting the brand-name medication. While the active ingredient, loteprednol, is found in other products, Eysuvis's unique formulation for short-term dry eye flare-ups is not yet available in a lower-cost generic form.

Verzenio, with the active ingredient abemaciclib, was first approved by the FDA in September 2017 to treat certain types of breast cancer. This groundbreaking medication is currently only available as a brand-name drug, which prompts many patients to ask: **Is there a generic drug for Verzenio?**.

On July 15, 2019, the patent for the brand-name drug FIRAZYR (icatibant injection) officially expired in the United States, which paved the way for generic versions. The answer to the question, 'When did FIRAZYR go generic?' is not a single date but a series of launches that began shortly after its patent lapsed.

First approved by the FDA in 2021, Opzelura (ruxolitinib) remains a brand-name medication with no currently available generic version. This status is due to the robust patent protection that all innovative brand-name drugs receive, which prevents generic competition for a number of years.

Currently, there is no generic version of the brand-name medication Jakafi available in the United States. The drug is protected by patents held by its manufacturer, Incyte Corporation, which is a key factor impacting its availability and cost.